Overcoming resistance to PD-1 inhibitors: the synergistic anti-tumor effect with inflammatory factors

Area of Science:

• Oncology
• Immunology
• Cancer Therapy

Background:

• Tumors utilize the PD-1/PD-L1 pathway to evade immune responses.
• PD-1/PD-L1 inhibitors show broad-spectrum efficacy but limited response rates as monotherapy.
• Inflammatory factors interact with the PD-1/PD-L1 pathway and influence tumor development.

Purpose of the Study:

• To review the interplay between inflammatory factors and the PD-1/PD-L1 pathway.
• To explore the potential of combining inflammatory factors with PD-1 inhibitors to overcome resistance.
• To highlight the clinical risks associated with this combination strategy.

Main Methods:

• Literature review of studies on PD-1/PD-L1 pathway, inflammatory factors, and cancer immunotherapy.
• Analysis of synergistic anti-tumor effects between PD-1/PD-L1 inhibitors and inflammatory factors.
• Discussion of mechanisms regulating PD-L1 expression by inflammatory factors.

Main Results:

• PD-1/PD-L1 inhibitors and inflammatory factors demonstrate synergistic anti-tumor activity.
• Inflammatory factors can modulate PD-L1 expression, impacting tumor immunity.
• Combination therapy offers a potential strategy to reverse primary resistance to PD-1/PD-L1 inhibitors.

Conclusions:

• Combining inflammatory factors with PD-1 inhibitors is a promising approach to enhance anti-tumor immunity and overcome resistance.
• Careful consideration of potential risks, such as cytokine storm, is crucial for clinical application.
• Further research is warranted to optimize this combination strategy for cancer treatment.